Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 325

1.

Gender identity and sexual orientation affect health care satisfaction, but not utilization, in persons with Multiple Sclerosis.

Khayambashi S, Salter A, Tyry T, Cutter GR, Fox RJ, Marrie RA.

Mult Scler Relat Disord. 2020 Jan;37:101440. doi: 10.1016/j.msard.2019.101440. Epub 2019 Oct 12.

PMID:
32173004
2.

Using practice effects for targeted trials or sub-group analysis in Alzheimer's disease: How practice effects predict change over time.

Wang G, Kennedy RE, Goldberg TE, Fowler ME, Cutter GR, Schneider LS.

PLoS One. 2020 Feb 21;15(2):e0228064. doi: 10.1371/journal.pone.0228064. eCollection 2020.

3.

Functional gastrointestinal disorders negatively affect health-related quality of life in MS.

Marrie RA, Leung S, Tyry T, Cutter GR, Fox R, Salter A.

Neurol Clin Pract. 2019 Oct;9(5):381-390. doi: 10.1212/CPJ.0000000000000668.

PMID:
31750023
4.

Protocol for a systematically-developed, phase I/II, single-blind randomized controlled trial of treadmill walking exercise training effects on cognition and brain function in persons with multiple sclerosis.

Sandroff BM, Diggs MD, Bamman MM, Cutter GR, Baird JF, Jones CD, Rinker JR, Wylie GR, DeLuca J, Motl RW.

Contemp Clin Trials. 2019 Dec;87:105878. doi: 10.1016/j.cct.2019.105878. Epub 2019 Nov 5.

PMID:
31704437
5.

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.

Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators.

Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5.

PMID:
31495497
6.

Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.

Gaston TE, Bebin EM, Cutter GR, Ampah SB, Liu Y, Grayson LP, Szaflarski JP; UAB CBD Program.

Epilepsy Behav. 2019 Sep;98(Pt A):201-206. doi: 10.1016/j.yebeh.2019.07.008. Epub 2019 Aug 2.

PMID:
31382177
7.

Early complement genes are associated with visual system degeneration in multiple sclerosis.

Fitzgerald KC, Kim K, Smith MD, Aston SA, Fioravante N, Rothman AM, Krieger S, Cofield SS, Kimbrough DJ, Bhargava P, Saidha S, Whartenby KA, Green AJ, Mowry EM, Cutter GR, Lublin FD, Baranzini SE, De Jager PL, Calabresi PA.

Brain. 2019 Sep 1;142(9):2722-2736. doi: 10.1093/brain/awz188.

PMID:
31289819
8.

Developing a crosswalk between the RAND-12 and the health utilities index for multiple sclerosis.

Marrie RA, Dufault B, Tyry T, Cutter GR, Fox RJ, Salter A.

Mult Scler. 2019 Jun 4:1352458519852722. doi: 10.1177/1352458519852722. [Epub ahead of print]

PMID:
31161917
9.

Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life.

Boscoe AN, Xin H, LʼItalien GJ, Harris LA, Cutter GR.

J Clin Neuromuscul Dis. 2019 Jun;20(4):173-181. doi: 10.1097/CND.0000000000000257.

10.

CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.

Yanik MV, Seifert ME, Locke JE, Hauptfeld-Dolejsek V, Crowley MR, Cutter GR, Mannon RB, Feig DI, Limdi NA.

Pediatr Transplant. 2019 Aug;23(5):e13494. doi: 10.1111/petr.13494. Epub 2019 May 24.

PMID:
31124575
11.

Hand stereotypies: Lessons from the Rett Syndrome Natural History Study.

Stallworth JL, Dy ME, Buchanan CB, Chen CF, Scott AE, Glaze DG, Lane JB, Lieberman DN, Oberman LM, Skinner SA, Tierney AE, Cutter GR, Percy AK, Neul JL, Kaufmann WE.

Neurology. 2019 May 28;92(22):e2594-e2603. doi: 10.1212/WNL.0000000000007560. Epub 2019 May 3.

PMID:
31053667
12.

Video Telehealth Pulmonary Rehabilitation Intervention in Chronic Obstructive Pulmonary Disease Reduces 30-Day Readmissions.

Bhatt SP, Patel SB, Anderson EM, Baugh D, Givens T, Schumann C, Sanders JG, Windham ST, Cutter GR, Dransfield MT.

Am J Respir Crit Care Med. 2019 Aug 15;200(4):511-513. doi: 10.1164/rccm.201902-0314LE. No abstract available.

PMID:
30978302
13.

The prevalence of MS in the United States: A population-based estimate using health claims data.

Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Tremlett H, Buka SL, Dilokthornsakul P, Topol B, Chen LH, LaRocca NG; US Multiple Sclerosis Prevalence Workgroup.

Neurology. 2019 Mar 5;92(10):e1029-e1040. doi: 10.1212/WNL.0000000000007035. Epub 2019 Feb 15. Erratum in: Neurology. 2019 Oct 8;93(15):688.

14.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25.

15.

Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.

Kennedy RE, Cutter GR, Fowler ME, Schneider LS.

JAMA Netw Open. 2018 Nov 2;1(7):e184080. doi: 10.1001/jamanetworkopen.2018.4080.

16.

Rationale and design of a single-blind, randomised controlled trial of exercise training for managing learning and memory impairment in persons with multiple sclerosis.

Sandroff BM, Motl RW, Bamman M, Cutter GR, Bolding M, Rinker JR, Wylie GR, Genova H, DeLuca J.

BMJ Open. 2018 Dec 14;8(12):e023231. doi: 10.1136/bmjopen-2018-023231.

17.

Implementation of Occupational Sun Safety at a 2-Year Follow-Up in a Randomized Trial: Comparison of Sun Safe Workplaces Policy Intervention to Attention Control.

Buller DB, Walkosz BJ, Buller MK, Wallis A, Andersen PA, Scott MD, Meenan RT, Cutter GR.

Am J Health Promot. 2019 Jun;33(5):683-697. doi: 10.1177/0890117118814398. Epub 2018 Nov 26.

PMID:
30477333
18.

Use of eHealth and mHealth technology by persons with multiple sclerosis.

Marrie RA, Leung S, Tyry T, Cutter GR, Fox R, Salter A.

Mult Scler Relat Disord. 2019 Jan;27:13-19. doi: 10.1016/j.msard.2018.09.036. Epub 2018 Oct 2.

PMID:
30296732
19.

Short-term disability progression in two multiethnic multiple sclerosis centers in the treatment era.

Kister I, Bacon TE, Cutter GR.

Ther Adv Neurol Disord. 2018 Sep 11;11:1756286418793613. doi: 10.1177/1756286418793613. eCollection 2018.

20.

Medical Rehabilitation: Guidelines to Advance the Field With High-Impact Clinical Trials.

Bamman MM, Cutter GR, Brienza DM, Chae J, Corcos DM, DeLuca S, Field-Fote E, Fouad MN, Lang CE, Lindblad A, Motl RW, Perna CG, Reisman D, Saag KM, Savitz SI, Schmitz KH, Stevens-Lapsley J, Whyte J, Winstein CJ, Michel ME.

Arch Phys Med Rehabil. 2018 Dec;99(12):2637-2648. doi: 10.1016/j.apmr.2018.08.173. Epub 2018 Aug 24.

PMID:
30148997
21.

An introduction to Mendelian randomization with applications in neurology.

Allman PH, Aban IB, Tiwari HK, Cutter GR.

Mult Scler Relat Disord. 2018 Aug;24:72-78. doi: 10.1016/j.msard.2018.06.017. Epub 2018 Jun 20. Review.

PMID:
29960142
22.

Phase-III, randomized controlled trial of the behavioral intervention for increasing physical activity in multiple sclerosis: Project BIPAMS.

Motl RW, Sandroff BM, Wingo BC, McCroskey J, Pilutti LA, Cutter GR, Bollaert RE, McAuley E.

Contemp Clin Trials. 2018 Aug;71:154-161. doi: 10.1016/j.cct.2018.06.017. Epub 2018 Jun 27.

PMID:
29959105
23.

Divergent effects of AKI to CKD models on inflammation and fibrosis.

Black LM, Lever JM, Traylor AM, Chen B, Yang Z, Esman SK, Jiang Y, Cutter GR, Boddu R, George JF, Agarwal A.

Am J Physiol Renal Physiol. 2018 Oct 1;315(4):F1107-F1118. doi: 10.1152/ajprenal.00179.2018. Epub 2018 Jun 13.

24.

Understanding and Preventing Loss to Follow-up: Experiences From the Spinal Cord Injury Model Systems.

Kim H, Cutter GR, George B, Chen Y.

Top Spinal Cord Inj Rehabil. 2018 Spring;24(2):97-109. doi: 10.1310/sci2402-97.

25.

Phase II Randomized Controlled Trial of Constraint-Induced Movement Therapy in Multiple Sclerosis. Part 1: Effects on Real-World Function.

Mark VW, Taub E, Uswatte G, Morris DM, Cutter GR, Adams TL, Bowman MH, McKay S.

Neurorehabil Neural Repair. 2018 Mar;32(3):223-232. doi: 10.1177/1545968318761050.

26.

Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study.

Murphy SL, Barber MW, Homer K, Dodge C, Cutter GR, Khanna D.

Arthritis Care Res (Hoboken). 2018 Nov;70(11):1653-1660. doi: 10.1002/acr.23522.

27.

Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE.

Hussain RZ, Miller-Little WA, Doelger R, Cutter GR, Loof N, Cravens PD, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e437. doi: 10.1212/NXI.0000000000000437. eCollection 2018 Mar.

28.

A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression.

Iacoviello BM, Murrough JW, Hoch MM, Huryk KM, Collins KA, Cutter GR, Iosifescu DV, Charney DS.

NPJ Digit Med. 2018;1. pii: 21. doi: 10.1038/s41746-018-0025-5. Epub 2018 Jun 6.

29.

Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis.

Wang G, Marrie RA, Fox RJ, Tyry T, Cofield SS, Cutter GR, Salter A.

Mult Scler Relat Disord. 2018 Feb;20:16-21. doi: 10.1016/j.msard.2017.12.006. Epub 2017 Dec 14.

PMID:
29275057
30.

Perspectives on marijuana use and effectiveness: A survey of NARCOMS participants.

Cofield SS, Salter A, Tyry T, Crowe C, Cutter GR, Fox RJ, Marrie RA.

Neurol Clin Pract. 2017 Aug;7(4):333-343. doi: 10.1212/CPJ.0000000000000383.

31.

Prevalence of Sun Protection at Outdoor Recreation and Leisure Venues at Resorts in North America.

Walkosz BJ, Scott MD, Buller DB, Andersen PA, Beck L, Cutter GR.

Am J Health Educ. 2017;48(2):90-99. doi: 10.1080/19325037.2016.1271755. Epub 2017 Mar 10.

32.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

33.

Trigeminal Neuralgia Commonly Precedes the Diagnosis of Multiple Sclerosis.

Fallata A, Salter A, Tyry T, Cutter GR, Marrie RA.

Int J MS Care. 2017 Sep-Oct;19(5):240-246. doi: 10.7224/1537-2073.2016-065.

34.

Pedestrian safety in patients with Parkinson's disease: A case-control study.

Ford KJ, Joop A, Memon RA, Wood KH, Ball K, Cutter GR, Schwebel DC, Amara AW.

Mov Disord. 2017 Dec;32(12):1748-1755. doi: 10.1002/mds.27124. Epub 2017 Oct 4.

35.

Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Fox RJ.

Neurology. 2017 Sep 26;89(13):1429-1430. doi: 10.1212/WNL.0000000000004437. No abstract available.

PMID:
28947584
36.

Prevalence odds ratio versus prevalence ratio: choice comes with consequences.

Tamhane AR, Westfall AO, Burkholder GA, Cutter GR.

Stat Med. 2017 Oct 15;36(23):3760. doi: 10.1002/sim.7375. Epub 2017 Jul 6. No abstract available.

PMID:
28872254
37.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11. Review.

38.

Interactions between cannabidiol and commonly used antiepileptic drugs.

Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP; UAB CBD Program.

Epilepsia. 2017 Sep;58(9):1586-1592. doi: 10.1111/epi.13852. Epub 2017 Aug 6.

39.

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.

Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, Steinerman JR, Knappertz V.

Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e358. doi: 10.1212/NXI.0000000000000358. eCollection 2017 Jul.

40.

Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease.

Hussain RZ, Miller-Little WA, Lambracht-Washington D, Jaramillo TC, Takahashi M, Zhang S, Fu M, Cutter GR, Hayardeny L, Powell CM, Rosenberg RN, Stüve O.

J Neuroimmunol. 2017 Aug 15;309:100-110. doi: 10.1016/j.jneuroim.2017.05.017. Epub 2017 May 26.

PMID:
28601278
41.

Erratum to: Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.

Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki EM, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG.

Osteoporos Int. 2017 Aug;28(8):2505. doi: 10.1007/s00198-017-4105-1. No abstract available.

PMID:
28593448
42.

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

Kennedy RE, Cutter GR, Wang G, Schneider LS.

Am J Geriatr Psychiatry. 2017 Oct;25(10):1150-1159. doi: 10.1016/j.jagp.2017.04.013. Epub 2017 Apr 25.

43.

Assessing the feasibility of the Effectiveness of Discontinuing Bisphosphonates trial: a pilot study.

Wright NC, Foster PJ, Mudano AS, Melnick JA, Lewiecki EM, Shergy WJ, Curtis JR, Cutter GR, Danila MI, Kilgore ML, Lewis EC, Morgan SL, Redden DT, Warriner AH, Saag KG.

Osteoporos Int. 2017 Aug;28(8):2495-2503. doi: 10.1007/s00198-017-4073-5. Epub 2017 May 24. Erratum in: Osteoporos Int. 2017 Jun 7;:.

44.

A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry.

Salter A, Thomas NP, Tyry T, Cutter GR, Marrie RA.

Mult Scler. 2018 Jun;24(7):951-962. doi: 10.1177/1352458517711274. Epub 2017 May 19.

PMID:
28524746
45.

The Virtual Short Physical Performance Battery: Psychometric Properties and Validation in Older Adults With Multiple Sclerosis.

Bollaert RE, Marsh AP, Cutter GR, Motl RW.

J Appl Gerontol. 2019 Oct;38(10):1492-1505. doi: 10.1177/0733464817709532. Epub 2017 May 15.

PMID:
28506093
46.

Neurocognitive Predictors of Declining Financial Capacity in Persons with Mild Cognitive Impairment.

Niccolai LM, Triebel KL, Gerstenecker A, McPherson TO, Cutter GR, Martin RC, Marson DC.

Clin Gerontol. 2017 Jan-Feb;40(1):14-23. doi: 10.1080/07317115.2016.1228022. Epub 2016 Sep 1.

47.

Upper limb impairment is associated with use of assistive devices and unemployment in multiple sclerosis.

Marrie RA, Cutter GR, Tyry T, Cofield SS, Fox R, Salter A.

Mult Scler Relat Disord. 2017 Apr;13:87-92. doi: 10.1016/j.msard.2017.02.013. Epub 2017 Feb 20.

PMID:
28427709
48.

Association Between Early Childhood Caries and Colonization with Streptococcus mutans Genotypes From Mothers.

Childers NK, Momeni SS, Whiddon J, Cheon K, Cutter GR, Wiener HW, Ghazal TS, Ruby JD, Moser SA.

Pediatr Dent. 2017 Mar 15;39(2):130-135.

49.

Evaluating risk factors for chronic kidney disease in pediatric patients with sickle cell anemia.

Lebensburger JD, Cutter GR, Howard TH, Muntner P, Feig DI.

Pediatr Nephrol. 2017 Sep;32(9):1565-1573. doi: 10.1007/s00467-017-3658-8. Epub 2017 Apr 5.

50.

High hypothetical interest in physician-assisted death in multiple sclerosis.

Marrie RA, Salter A, Tyry T, Cutter GR, Cofield S, Fox RJ.

Neurology. 2017 Apr 18;88(16):1528-1534. doi: 10.1212/WNL.0000000000003831. Epub 2017 Mar 15.

PMID:
28298551

Supplemental Content

Loading ...
Support Center